about
BRAF mutations in hairy-cell leukemiaNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyTargeted Therapy in Systemic SclerosisNovel small molecule Raf kinase inhibitors for targeted cancer therapeuticsDifferential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cellsTargeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFαMolecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and ImmunotherapyEssential genetic and genomic nursing competencies for the oncology nurse.Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran.Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptorDevelopment of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimizationBraf and erbB2 mutations correlate with smoking status in lung cancer patients.Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forcesEffect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient.Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Therapy for metastatic melanoma: an overview and update.Towards new therapeutic approaches for malignant melanoma.Cutaneous effects of BRAF inhibitor therapy: a case series.Lessons from next-generation sequencing analysis in hematological malignancies.How, and from which cell sources, do nevi really develop?Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.MAPK pathway inhibition in melanoma: resistance three ways.Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Adolescent and young adult patients with cancer: a milieu of unique features.Current position of TNF-α in melanomagenesis.Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.Heterogeneous tumor subpopulations cooperate to drive invasion.The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases.Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
P2860
Q24609980-350273B4-EB44-403E-ACC8-6FAB26571962Q24628724-43CF450F-1AE9-457D-BBAD-10D9597C2E21Q28072943-91E0CB85-C181-4D6D-9D89-8BBDC12D959EQ28265862-808BA91F-02BE-408E-BF5B-8A301438D97FQ33838195-6CA35837-171E-46BB-9159-B5F7BE197D8BQ34222257-5112918E-11CE-4725-AF3C-2AB73133473FQ34287452-BD6158D0-B168-42F9-AE1B-83854A9F8A03Q34446657-36B6D1E2-5AB8-470E-9064-611D269F5ADDQ34671658-7B74C108-C691-4A4F-97DE-C3FAAC125AB9Q34685938-DC24CA35-66D6-4F8D-8C4D-D7E52010C082Q35023498-EFDFDA6E-8198-4647-B757-546BDACDF1ADQ35930021-E5C59690-BF87-4487-8421-F0DE8D6588DAQ36059811-2C02EE13-FC69-41FC-AFE5-F175DB99F89FQ36078281-C964C1CF-D294-437B-8ADC-3FDD8EE2F2DBQ36189476-AA4751B5-CF0B-433A-A9EC-AFEBCCDE1164Q36224108-0849861C-3FF4-4F5B-AC97-DE2DFB585588Q36507245-109C76C1-0EAD-436C-887E-B79F9E868196Q36507554-4150A026-37DA-41E5-B6D2-0EB47A3478F2Q36743955-57D75D86-6FFB-466F-9730-92A075FEF355Q36926143-1959082B-2AE8-4B6D-B9AC-576CBC678414Q37632230-2CB88808-E0AD-45AF-B384-41777CFDD978Q37873464-4EDA10CB-E200-45D6-826D-149C259931D7Q37951743-FF374F78-AEF4-48DE-A6F7-8AD5B0D93CADQ38049306-71176355-98C5-4EAE-B4F3-6A19AE976F18Q38123015-E5685596-5118-44FE-A1FA-4A5424053838Q38192727-236FF078-3B3A-4EAF-9A60-D790CFB800AAQ38225118-B45DEEA8-0481-43D3-A85A-9093EC70E634Q38228386-DC16189E-0243-4A98-94AB-5D417E65A810Q38238597-CF516924-69E3-4E7C-939D-98E54DD79ED4Q38357122-9B973B67-F237-49A0-B884-5F9DE3EF6EAFQ38502885-65D2C767-E48C-40A5-826C-1EA77F6E75C8Q38567932-D70E365C-51E8-4518-9F7C-24B0C060E6E6Q38951511-E8E71F06-B7BA-475D-8B44-639CCE3F3998Q38971257-CD168249-A80A-4661-AA0A-767B9C08757DQ39017645-570CF30D-A787-48C3-809D-A5BF0ECD7C40Q39186157-35FA4C17-93F6-45BF-904F-0D3FFAECFBB8Q39609077-0E3D1753-9146-4970-8E2C-1BA72D5C2BBBQ40180256-91D3E8A6-13C1-45D1-A1B0-D47F8836B1EFQ41858647-E3709882-D1F4-42FB-B360-F95932711B9EQ42206973-C98C8B0D-971E-45BF-88E6-A13D164290A5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BRAF as therapeutic target in melanoma.
@en
BRAF as therapeutic target in melanoma.
@nl
type
label
BRAF as therapeutic target in melanoma.
@en
BRAF as therapeutic target in melanoma.
@nl
prefLabel
BRAF as therapeutic target in melanoma.
@en
BRAF as therapeutic target in melanoma.
@nl
P1476
BRAF as therapeutic target in melanoma.
@en
P304
P356
10.1016/J.BCP.2010.03.019
P407
P577
2010-03-27T00:00:00Z